The biotech company Moderna has dosed the first of 600 volunteers in the next phase of testing for its vaccine against the Covid-19 virus, saying Friday that it gave the vaccine to people in each of the two groups it will test—adults under 55 and those older. Goldman Sachs analyst Salveen Richter expressed optimism about the vaccine in a Monday note. She reiterated her Buy recommendation on the stock and said she thinks the vaccine test has a 75% probability of success. Barron's
Monday, June 1, 2020
Moderna’s Covid-19 Vaccine Enters Next Phase of Testing. Goldman Sachs Is Upbeat.
The biotech company Moderna has dosed the first of 600 volunteers in the next phase of testing for its vaccine against the Covid-19 virus, saying Friday that it gave the vaccine to people in each of the two groups it will test—adults under 55 and those older. Goldman Sachs analyst Salveen Richter expressed optimism about the vaccine in a Monday note. She reiterated her Buy recommendation on the stock and said she thinks the vaccine test has a 75% probability of success. Barron's
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment